Goldman Sachs initiated coverage of Ardent Health (ARDT) with a Neutral rating and $19 price target The firm sees favorable trends continuing for the hospital sector through 2028, including supportive labor dynamics, tailwinds from previously approved pro-utilization government policies, and the industry showing more effective adaptation to structural changes. However, the sector will face new pressures from implementation of the One Big Beautiful Bill, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health Partners Amends Credit Agreements for Flexibility
- Ardent Health Partners: Buy Rating Affirmed Amid Growth Potential and Attractive Valuation
- Ardent Health initiated with a Buy at UBS
- Ardent Health files $500M mixed securities shelf
- Ardent Health files to sell 120.45M shares of common stock for holders